Phase I Trial of Selinexor (KPT-330) and Ifosfamide, Carboplatin, Etoposide (ICE) in Peripheral T-cell Lymphoma
Status:
Completed
Trial end date:
2020-11-01
Target enrollment:
Participant gender:
Summary
This is a single center, open-label, phase I trial with a standard 3+3 dose escalation schema
to identify the maximum tolerated dose (MTD) of selinexor when combined with ICE. Once MTD is
determined, there will be an expansion phase and tumor biopsies and peripheral blood will be
taken pre and post selinexor to examine the study's biologic objectives.